Literature DB >> 8866769

Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man.

S Nyberg1, A L Nordström, C Halldin, L Farde.   

Abstract

Positron emission tomography (PET) and the selective radioligand [11C]raclopride were used to measure D2 receptor occupancy in several studies in schizophrenic patients and healthy subjects. Clinical effects of the treatment were recorded, and drug plasma concentrations measured. The hypothesized curvilinear relationship between receptor occupancy and drug plasma concentrations was supported experimentally. We suggest that there may be a distinct threshold for antipsychotic effect at about 70% D2 receptor occupancy, and another threshold for extrapyramidal side effects above 80% D2 receptor occupancy. Receptor occupancy was high even at low plasma drug concentrations. Our data indicate a need to establish dose-response curves for the conventional neuroleptics. Such a dose-response relationship might be expected for a much lower dose interval than those previously examined.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8866769

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  14 in total

1.  Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Authors:  M Reimold; C Solbach; S Noda; J-E Schaefer; M Bartels; M Beneke; H-J Machulla; R Bares; T Glaser; H Wormstall
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Functional imaging of the brain in the evaluation of drug response and its application to the study of aging.

Authors:  C A Bryant; S H Jackson
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 3.923

4.  Haloperidol 2 mg impairs inhibition but not visuospatial attention.

Authors:  H N Alexander Logemann; Koen B E Böcker; Peter K H Deschamps; Peter N van Harten; Jeroen Koning; Chantal Kemner; Zsófia Logemann-Molnár; J Leon Kenemans
Journal:  Psychopharmacology (Berl)       Date:  2016-10-17       Impact factor: 4.530

5.  Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia.

Authors:  Ornella Valenti; Pierangelo Cifelli; Kathryn M Gill; Anthony A Grace
Journal:  J Neurosci       Date:  2011-08-24       Impact factor: 6.167

Review 6.  First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.

Authors:  Thomas W Weickert; Terry E Goldberg
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

7.  Influence of risperidone on balance control in young healthy individuals.

Authors:  Philippe Corbeil; Julien Rodrigue; Martin Simoneau; Henri Cohen; Emmanuelle Pourcher
Journal:  Psychopharmacology (Berl)       Date:  2012-01-11       Impact factor: 4.530

8.  Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats.

Authors:  Tafheem Malik; Sheema Hasan; Shahid Pervez; Tasneem Fatima; Darakhshan Jabeen Haleem
Journal:  Neurochem Res       Date:  2016-10-18       Impact factor: 3.996

9.  Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.

Authors:  W G Frankle; R Gil; E Hackett; O Mawlawi; Y Zea-Ponce; Z Zhu; L D Kochan; C Cangiano; M Slifstein; J M Gorman; M Laruelle; A Abi-Dargham
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

10.  123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia.

Authors:  Hans Sjøholm; Trond Bratlid; Johan Sundsfjord
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.